The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

26 Jul 2013 07:00

RNS Number : 1983K
Sopheon PLC
26 July 2013
 



Embargoed Release: 07:00hrs Friday 26 July 2013

SOPHEON PLC

 

("Sopheon" or the "Company")

 

TRADING UPDATE

 

Sopheon plc, the internationalprovider of software and services that improve the financial return from innovation and product development investments, issues the following trading update for the six months to 30 June 2013.

 

In our Annual General Meeting announcement issued on 12 June, we noted that we had a substantial amount of business to close by the end of June. A good proportion has concluded successfully. Accordingly, revenue visibility is now £10.3 million, compared to just over £8 million at the time of the Annual General Meeting and £9.6 million a year ago. Thanks to these sales, we expect first half revenue to moderately exceed revenues for the corresponding period last year. As previously announced, we have continued a controlled expansion of staff levels in all parts of the business. These actions, coupled with the full-year effect of additional staff added during 2012, mean that our costs also exceed the previous year and accordingly the reported EBITDA result is expected to be moderately lower.

 

Further details of the results for the six months to 30 June 2013 will be provided in our interim financial report, scheduled for release on 22 August 2013. Expectations noted above are subject to completion of the period-end financial close and auditor review processes. Looking forward to the second half of the year, our sales pipeline remains strong. However, we would note that, as always in our industry, accurate prediction of the timing and value of sales events can be difficult.

 

Since our Annual General Meeting we have also completed the first phase of our corporate restructuring, to reduce the number of shares in issue by a factor of 20. This was successfully achieved through a two-step process involving a 10000:1 share consolidation followed by a 1:500 share subdivision one week later, in accordance with the circular issued to shareholders at the start of May. Overall, this has reduced the number of shares in issue from 145.6 million shares to 7.3 million shares. The nominal value of each share has changed from 5p to 20p. This procedure also reduced the number of shareholders on the Company's UK register from approximately 4000 to approximately 200. As previously explained these figures do not include shareholders in the Dutch system, which were anticipated to fall from over 7000 shareholders to under 2000 shareholders. Due to differences in the way that shares are held in the Netherlands, we have yet to establish the precise impact on Dutch holdings at this time but continue to make appropriate enquiries and will update the market as and when appropriate. We aim to complete the second phase of our restructuring, the elimination of the accumulated deficit on the profit and loss account, later this year, as planned.

For further information contact:

 

Barry Mence, Chairman

Sopheon plc

+ 44 (0) 1483 685 735

Arif Karimjee, CFO

Sopheon plc

+ 44 (0) 1483 685 735

Charlotte Stranner / Victoria Bates

finnCap

+ 44 (0) 20 7600 1658

Josh Royston / Heather Armstrong

Newgate Threadneedle

+ 44 (0) 20 7653 9850

Claire Verhagen

Citigate First Financial

+ 31 (0) 205 754 010

 

About Sopheon

Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Performance solutions including software, expertise, and best-practices to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade® solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle. For the first time, businesses can access a single source of the truth across strategic innovation planning, roadmapping, idea and concept development, process and project management, and portfolio and in-market management. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange and on the Alternext Exchange in the Netherlands. For more information, please visit www.sopheon.com

Revenue visibility is defined in Note4 of Sopheon's 2012 annual report which is available from the investor section of www.sopheon.com .

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQELFLXDFZBBK
Date   Source Headline
11th Apr 20167:00 amRNSDirectors Options and Shareholding
21st Mar 20167:00 amRNSAmendment to Terms of Convertible Loan Stock
17th Mar 20167:00 amRNSFinal Results
21st Jan 20168:29 amRNSAccolade Release 10.2
8th Jan 20167:00 amRNSTrading Update and Board Change
20th Oct 20159:33 amRNSDirector Dealing
19th Oct 20157:00 amRNSDirector Dealing
9th Oct 20153:41 pmRNSDirector Dealing
9th Oct 20151:12 pmRNSDirector Dealing
2nd Oct 20153:39 pmRNSDirector Dealing
23rd Sep 20157:00 amRNSAccolade Release 10.1
27th Aug 20157:01 amRNSHalf Yearly Report
1st Jul 20157:00 amRNSDirector Shareholding
10th Jun 20151:44 pmRNSResult of AGM
10th Jun 20157:00 amRNSAGM Statement
2nd Jun 20157:00 amRNSAccolade 10.0 release
15th May 20153:10 pmRNSNotice of AGM
7th May 201511:40 amRNSDIRECTOR SHAREHOLDING
23rd Apr 201511:10 amRNSDirector Shareholding
20th Apr 201511:43 amRNSDirector Shareholding
13th Apr 20152:03 pmRNSHolding(s) in Company
10th Apr 201511:05 amRNSHolding(s) in Company
8th Apr 20157:00 amRNSDELISTING FROM ALTERNEXT AMSTERDAM
19th Mar 20157:00 amRNSFinal Results
20th Feb 20157:00 amRNSSopheon Releases Accolade® 9.3
5th Feb 20154:12 pmRNSChange of Registered Office
28th Jan 20157:00 amRNSTrading Update
19th Dec 201410:30 amRNSResult of General Meeting
12th Dec 20143:00 pmRNSTrading Update
2nd Dec 20144:00 pmRNSProposed Share Subdivision
2nd Dec 20147:00 amRNSDirector/PDMR Shareholding
27th Oct 20144:15 pmRNSDirector/PDMR Shareholding
22nd Oct 20143:45 pmRNSDirector/PDMR Shareholding
21st Oct 20147:00 amRNSDirector/PDMR Shareholding
17th Oct 20141:50 pmRNSDirector/PDMR Shareholding
10th Oct 201411:15 amRNSResult of GM and Further re Share Consolidation
24th Sep 20147:00 amRNSAccolade 9.2 Release
12th Sep 20147:00 amRNSShare Consolidation
28th Aug 20147:00 amRNSHalf Yearly Report
11th Jun 201412:20 pmRNSResult of AGM
11th Jun 20147:00 amRNSAGM Statement
2nd Jun 20147:00 amRNSAmendment To The Terms Of Convertible Loan Stock
22nd May 20147:00 amRNSAlternext Amsterdam
1st May 20147:00 amRNSInterim Management Statement
22nd Apr 20147:01 amRNSSopheon Delivers Accolade Release 9.1
11th Apr 20147:00 amRNSWind Down Of Alternext Amsterdam
20th Mar 20147:01 amRNSTotal Voting Rights
20th Mar 20147:00 amRNSPreliminary Results
6th Mar 20147:00 amRNSNew Debt Facility
29th Jan 20148:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.